Cadila Healthcare – Receives Emergency Use Authorisation From DCGI For ZyCov-D Covid Vaccine: KRChoksey

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

KRChoksey Research Report

Cadila Healthcare Ltd. has received the emergency use authorisation from the Drug Controller General of India for ZyCOV–D vaccine.

It is believed to be the first Plasmid DNA vaccine for Covid–19 in the world.

It is a three-dose vaccine, which will be administered with the gap of 28 days from each other, thrice, to the individual.

The pricing for the vaccine (which is likely to be announced sooner) will be per dose basis, and not on the treatment basis.

It is the first Covid-19 vaccine for adolescents in the age group of 12-18, besides for adult population.

Cadila Healthcare’s ZyCOV-D is a needle free vaccine, which will be administered, using the PharmaJet (a needle free applicator), which enables painless intradermal vaccine delivery.

Click on the attachment to read the full report:

KRChoksey Cadila HealthCare Event Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button